Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

Overview

The purpose of this study is to find out what effects (good and bad) a stem cell transplant from an unrelated donor will have for patients with kidney cancer that has spread to other parts of the body (metastasized).

Full Title of Study: “Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2009

Detailed Description

Standard treatment for kidney cancer that has spread to other parts of the body may include immunotherapy (a therapy that uses the body's natural immune system to fight cancer) and cytokines (proteins found in the body). If these treatments are not successful at controlling the cancer then chemotherapy or thalidomide are used. Chemotherapy and thalidomide will not cure kidney cancer but they may control the disease in some patients. In some patients, transplants are now proposed for study. Stem cells (from bone marrow or the bloodstream) are normally used to treat cancers of the blood, not kidney cancer. Since researchers are still learning about using stem cell transplants for kidney cancer, the study is considered a research study. Patients participating in this study will receive smaller doses of chemotherapy drugs to prepare them for the transplant than patients who have a standard transplant. This type of transplant is called a "reduced intensity" transplant. A reduced intensity transplant uses the cell-killing activity of the transplanted donor stem cells to attack the recipient's cancer cells. This is called graft-versus-tumor-effect (GVT). Previous studies have shown that GVT may be greater if the donor is not related to the recipient.

Interventions

  • Procedure: NST using MUD for metastatic renal cell carcinoma
    • Preparative regimen: Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11

Arms, Groups and Cohorts

  • Experimental: MUD treatment
    • NST using MUD for metastatic renal cell carcinoma

Clinical Trial Outcome Measures

Primary Measures

  • Determine the best rate of tumor response of complete response (CR) + complete unconfirmed response (CRU) + partial response (PR) within 6 months after matched unrelated donor (MUD) nonmyeloablative stem cell transplantation (NST)
    • Time Frame: 6 months

Secondary Measures

  • Overall survival after MUD NST
    • Time Frame: Two years
  • Rate of complete donor myeloid and lymphoid chimerism after MUD NST
    • Time Frame: One year
  • Incidence and severity of acute and chronic graft-versus-host disease (GvHD) after MUD NST
    • Time Frame: Two years
  • Incidence of treatment-related mortality (TRM)
    • Time Frame: 100 Days
  • Assess cytotoxic T-lymphocyte reactivity
    • Time Frame: One year
  • Assess antibody activity against potential tumor antigenic peptides in graft-versus-renal cell carcinoma (RCC) effect
    • Time Frame: Six months

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of metastatic (stage IV) renal cell carcinoma (RCC) predominately clear cell type – Prior nephrectomy – Available HLA-matched (8/8, 7/8) unrelated donor – At least one prior immunotherapy; or immunotherapy + chemotherapy; or targeted therapy, for metastatic RCC. – Adequate organ function Exclusion Criteria:

  • Prior allogeneic stem cell transplantation – RCC with histology other than clear cell type – History or presence of brain metastasis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Center for International Blood and Marrow Transplant Research
  • Collaborator
    • M.D. Anderson Cancer Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Naoto Ueno, M.D., Ph.D., Study Chair, MDACC

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.